Microbial burden and viral exacerbations in a longitudinal multicenter COPD cohort
Open Access
- 30 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Respiratory Research
- Vol. 21 (1), 1-13
- https://doi.org/10.1186/s12931-020-01340-0
Abstract
Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease characterized by frequent exacerbation phenotypes independent of disease stage. Increasing evidence shows that the microbiota plays a role in disease progression and severity, but long-term and international multicenter assessment of the variations in viral and bacterial communities as drivers of exacerbations are lacking. Methods Two-hundred severe COPD patients from Europe and North America were followed longitudinally for 3 years. We performed nucleic acid detection for 20 respiratory viruses and 16S ribosomal RNA gene sequencing to evaluate the bacterial microbiota in 1179 sputum samples collected at stable, acute exacerbation and follow-up visits. Results Similar viral and bacterial taxa were found in patients from the USA compared to Bulgaria and Czech Republic but their microbiome diversity was significantly different (P < 0.001) and did not impact exacerbation rates. Virus infection was strongly associated with exacerbation events (P < 5E-20). Human rhinovirus (13.1%), coronavirus (5.1%) and influenza virus (3.6%) constitute the top viral pathogens in triggering exacerbation. Moraxella and Haemophilus were 5-fold and 1.6-fold more likely to be the dominating microbiota during an exacerbation event. Presence of Proteobacteria such as Pseudomonas or Staphylococcus amongst others, were associated with exacerbation events (OR > 0.17; P < 0.02) but more strongly associated with exacerbation frequency (OR > 0.39; P < 4E-10), as confirmed by longitudinal variations and biotyping of the bacterial microbiota, and suggesting a role of the microbiota in sensitizing the lung. Conclusions This study highlights bacterial taxa in lung sensitization and viral triggers in COPD exacerbations. It provides a global overview of the diverse targets for drug development and explores new microbiome analysis methods to guide future patient management applications.Keywords
Funding Information
- AstraZeneca
This publication has 58 references indexed in Scilit:
- Proposals for the classification of human rhinovirus species A, B and C into genotypically assigned typesJournal of General Virology, 2013
- Human gut microbiome viewed across age and geographyNature, 2012
- An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaeaThe ISME Journal, 2011
- Impact of training sets on classification of high-throughput bacterial 16s rRNA gene surveysThe ISME Journal, 2011
- Susceptibility to Exacerbation in Chronic Obstructive Pulmonary DiseaseThe New England Journal of Medicine, 2010
- Moraxella catarrhalisacquisition, airway inflammation and protease-antiprotease balance in chronic obstructive pulmonary diseaseBMC Infectious Diseases, 2009
- FastTree: Computing Large Minimum Evolution Trees with Profiles instead of a Distance MatrixMolecular Biology and Evolution, 2009
- Diversity of Human Vaginal Bacterial Communities and Associations with Clinically Defined Bacterial VaginosisApplied and Environmental Microbiology, 2008
- Quantitative and Qualitative β Diversity Measures Lead to Different Insights into Factors That Structure Microbial CommunitiesApplied and Environmental Microbiology, 2007
- Conservation evaluation and phylogenetic diversityBiological Conservation, 1992